uniQure (NASDAQ:QURE) Stock Price Down 4.2% – Should You Sell?

Shares of uniQure (NASDAQ:QURE) fell 4.2% during trading on Thursday . The stock traded as low as $12.99 and last traded at $13.08. 453,645 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 1,015,442 shares. The stock had previously closed at $13.65.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on QURE shares. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a report on Tuesday, March 11th. Mizuho boosted their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 19th. Stifel Nicolaus increased their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Down 5.0 %

The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market capitalization of $674.34 million, a PE ratio of -2.51 and a beta of 0.36. The firm’s 50-day simple moving average is $13.77 and its 200 day simple moving average is $10.75.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 90,830 shares of company stock worth $961,401. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. lifted its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of uniQure in the third quarter valued at $444,000. FMR LLC lifted its position in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC boosted its stake in shares of uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after acquiring an additional 34,034 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in uniQure during the 3rd quarter worth about $7,360,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.